全文获取类型
收费全文 | 7526篇 |
免费 | 473篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 199篇 |
儿科学 | 477篇 |
妇产科学 | 100篇 |
基础医学 | 784篇 |
口腔科学 | 240篇 |
临床医学 | 669篇 |
内科学 | 1741篇 |
皮肤病学 | 87篇 |
神经病学 | 552篇 |
特种医学 | 201篇 |
外科学 | 1073篇 |
综合类 | 227篇 |
一般理论 | 1篇 |
预防医学 | 336篇 |
眼科学 | 346篇 |
药学 | 515篇 |
中国医学 | 34篇 |
肿瘤学 | 461篇 |
出版年
2023年 | 62篇 |
2022年 | 140篇 |
2021年 | 358篇 |
2020年 | 164篇 |
2019年 | 211篇 |
2018年 | 259篇 |
2017年 | 199篇 |
2016年 | 228篇 |
2015年 | 264篇 |
2014年 | 368篇 |
2013年 | 394篇 |
2012年 | 606篇 |
2011年 | 583篇 |
2010年 | 337篇 |
2009年 | 251篇 |
2008年 | 442篇 |
2007年 | 483篇 |
2006年 | 370篇 |
2005年 | 320篇 |
2004年 | 303篇 |
2003年 | 271篇 |
2002年 | 229篇 |
2001年 | 111篇 |
2000年 | 90篇 |
1999年 | 88篇 |
1998年 | 57篇 |
1997年 | 39篇 |
1996年 | 25篇 |
1995年 | 23篇 |
1994年 | 29篇 |
1993年 | 26篇 |
1992年 | 57篇 |
1991年 | 67篇 |
1990年 | 58篇 |
1989年 | 52篇 |
1988年 | 50篇 |
1987年 | 44篇 |
1986年 | 37篇 |
1985年 | 41篇 |
1984年 | 16篇 |
1983年 | 28篇 |
1982年 | 14篇 |
1980年 | 13篇 |
1979年 | 31篇 |
1978年 | 18篇 |
1975年 | 21篇 |
1972年 | 21篇 |
1970年 | 14篇 |
1968年 | 13篇 |
1965年 | 13篇 |
排序方式: 共有8043条查询结果,搜索用时 15 毫秒
101.
102.
103.
104.
Anand Yuvaraj Anusha Rohit Priyanka Joseph Koshy P. Nagarajan Sanjeev Nair 《Renal failure》2014,36(9):1466-1467
A 68-year-old diabetic chronic kidney disease patient on continuous ambulatory peritoneal dialysis for two years developed Candida haemulonii peritonitis without any predisposing factors. There is no effective treatment for this fungus. A peritoneal biopsy showed morphological changes of acute inflammation and chronicity. 相似文献
105.
106.
107.
Robert S. Makar Anand Padmanabhan Haewon C. Kim Christina Anderson Michele W. Sugrue Michael Linenberger 《Transfusion medicine reviews》2014,28(4):198-204
Limited literature describes the value of laboratory “triggers” to guide collection of peripheral blood (PB) hematopoietic progenitor cells (HPCs) by apheresis [HPC(A)]. We used a web-based survey to determine which parameters are used to initiate autologous HPC(A) collection in adult and pediatric patients and to identify common practice patterns. Members of the AABB Cellular Therapy Product Collection and Clinical Practices Subsection and the American Society for Apheresis HPC Donor Subcommittee drafted and developed relevant survey questions. A web link to the survey was distributed by electronic newsletter or email. Responses from 67 programs that perform autologous HPC(A) collections, including academic medical centers (n = 46), blood centers (n = 10), community hospitals (n = 5), and a variety of other medical institutions (n = 6), were analyzed. Ninety-three percent (62/67) of programs used a laboratory parameter to initiate HPC(A) collection. In both adult (40/54, 74%) and pediatric (29/38, 76%) patients, the PB CD34 + cell count was the most common parameter used to initiate HPC(A) collection. The median PB CD34 + trigger value was 10/μL for both patient populations. Among centers routinely using the PB CD34 + cell count to initiate apheresis, 51% (22/43) first sent the test before the patient presented for collection. Although more than 90% of centers used a laboratory test to trigger apheresis in cytokine-mobilized (44/48) or chemomobilized patients (50/53), only 57% (30/53) used a laboratory trigger if the patient was mobilized with granulocyte colony-stimulating factor plus plerixafor. Forty-two percent (21/50) of programs that routinely measured the PB CD34 + count before collection and discontinued further HPC(A) collection based on product CD34 + cell yield also stopped if the PB CD34 + value before apheresis was considered too low to proceed. Most programs use the PB CD34 + cell count to trigger autologous HPC(A) collection. Some centers also use this parameter to stop further collections. Laboratory tests are used less frequently to initiate apheresis when patients are mobilized with plerixafor. These data reveal ongoing diversity in clinical practices and suggest that consensus guidelines on use of laboratory parameters may further optimize HPC(A) collection. 相似文献
108.
Yabin Cheng Jing Lu Guangdi Chen Gholamreza Safaee Ardekani Anand Rotte Magdalena Martinka Xuezhu Xu Kevin J. McElwee Guohong Zhang Youwen Zhou 《Oncotarget》2015,6(6):4180-4189
The melanoma staging system proposed by the American Joint Committee on Cancer (AJCC) (which classifies melanoma patients into four clinical stages) is currently the most widely used tool for melanoma prognostication, and clinical management decision making by clinicians. However, multiple studies have shown that melanomas within specific AJCC Stages can exhibit varying progression and clinical outcomes. Thus, additional information, such as that provided by biomarkers is needed to assist in identifying the patients at risk of disease progression.Having previously found six independent prognostic biomarkers in melanoma, including BRAF, MMP2, p27, Dicer, Fbw7 and Tip60, our group has gone on to investigate if these markers are useful in risk stratification of melanoma patients in individual AJCC stages. First, we performed Kaplan-Meier survival and Cox proportional multivariate analyses comparing prognostication power of these markers in 254 melanoma patients for whom the expression levels were known, identifying the best performing markers as candidates for stage-specific melanoma markers. We then verified the results by incorporating an additional independent cohort (87 patients) and in a combined cohort (341 patients).Our data indicate that BRAF and MMP2 are optimal prognostic biomarkers for AJCC Stages I and II, respectively (P = 0.010, 0.000, Log-rank test); whereas p27 emerged as a good marker for AJCC Stages III/IV (0.018, 0.046, respectively, log-rank test). Thus, our study has identified stage-specific biomarkers in melanoma, a finding which may assist clinicians in designing improved personalized therapeutic modalities. 相似文献
109.
110.